Rare diseases
Investigational molecules
Locations
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
BelgiumPhase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC
AustriaStudy of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing
BelgiumStudy of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BelgiumStudy on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer
BelgiumStudy of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer
FranceRinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer
CzechiaPhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
FranceSafety and Tolerability of Alisertib Sodium and Paclitaxel in Patients with Small Cell Lung Cancer (Phase 2 Study)
FranceStudy of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion
BelgiumSwitch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer
GermanyPhase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.
